Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment
Bauhinia purprea agglutinin (BPA) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA‐PEG‐modified liposomes (BPA...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2016-01, Vol.107 (1), p.53-59 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 59 |
|---|---|
| container_issue | 1 |
| container_start_page | 53 |
| container_title | Cancer science |
| container_volume | 107 |
| creator | Ikemoto, Keisuke Shimizu, Kosuke Ohashi, Kento Takeuchi, Yoshihito Shimizu, Motohiro Oku, Naoto |
| description | Bauhinia purprea agglutinin (BPA) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA‐PEG‐modified liposomes (BPA‐PEG‐LP) encapsulating anticancer drugs for the treatment of prostate cancer. We examined the tumor targetability of BPA‐PEG‐LP with human prostate cancer DU145 cells, and observed that fluorescently labeled BPA‐PEG‐LP dominantly associated with the cells via the interaction between liposome‐surface BPA and cell‐surface galactosyl molecules. We also observed that BPA‐PEG‐LP accumulated in the prostate cancer tissue after the i.v. injection to DU145 solid cancer‐bearing mice, and strongly bound to the cancer cells. In a therapeutic study, DU145 solid cancer‐bearing mice were i.v. injected thrice with BPA‐PEG‐LP encapsulating doxorubicin (BPA‐PEG‐LPDOX, 2 mg/kg/day as the DOX dosage) or PEG‐modified liposomes encapsulating DOX (PEG‐LPDOX). As a result, BPA‐PEG‐LPDOX significantly suppressed the growth of the DU145 cancer cells, whereas PEG‐LPDOX at the same dosage as DOX showed little anti‐cancer effect. The present study suggested that BPA‐PEG‐LP could be a useful drug carrier for the treatment of human prostate cancers.
BPA bound to human prostate cancer cells via the cell‐surface sugar chains terminating in galactose, resulting that BPA recognized to cancerous, but not to normal, human prostate tissue. |
| doi_str_mv | 10.1111/cas.12839 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4724813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2288102293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5379-6a1fba13ff3c6a9f24244b43d24f764d8d8df9712ae6b7d952c5a445167273843</originalsourceid><addsrcrecordid>eNp1kTtOxDAQhi0EYpdHwQVQJCqKgF-J4wZpWfGSkCiA2ppN7F2jJA52AqLjCJyRk2BYWEGBpxhr_PmfsX-E9gg-InEdlxCOCC2YXENjwrhMBcb5-tdepBIzOkJbITxgzHIu-SYa0ZgzickY3Z3CsLCthaQbfOc1JDCf10MfS-3761vjKmusrpLadi64RofEOJ8shgbapPMu9NDrpIS21D7p4_W-0W2_gzYM1EHvfudtdH9-dje9TK9vLq6mk-u0zJiQaQ7EzIAwY1iZgzSUU85nnFWUG5HzqohhpCAUdD4TlcxomQHnGckFFazgbBudLHW7YdboqoytPdSq87YB_6IcWPX3pLULNXdPigvKC8KiwMG3gHePgw69enCDb-PMitKiIJhS-UkdLqkyPjh4bVYdCFafBqhogPoyILL7v0dakT8_HoHjJfBsa_3yv5KaTm6Xkh_XRJJD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2288102293</pqid></control><display><type>article</type><title>Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><creator>Ikemoto, Keisuke ; Shimizu, Kosuke ; Ohashi, Kento ; Takeuchi, Yoshihito ; Shimizu, Motohiro ; Oku, Naoto</creator><creatorcontrib>Ikemoto, Keisuke ; Shimizu, Kosuke ; Ohashi, Kento ; Takeuchi, Yoshihito ; Shimizu, Motohiro ; Oku, Naoto</creatorcontrib><description>Bauhinia purprea agglutinin (BPA) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA‐PEG‐modified liposomes (BPA‐PEG‐LP) encapsulating anticancer drugs for the treatment of prostate cancer. We examined the tumor targetability of BPA‐PEG‐LP with human prostate cancer DU145 cells, and observed that fluorescently labeled BPA‐PEG‐LP dominantly associated with the cells via the interaction between liposome‐surface BPA and cell‐surface galactosyl molecules. We also observed that BPA‐PEG‐LP accumulated in the prostate cancer tissue after the i.v. injection to DU145 solid cancer‐bearing mice, and strongly bound to the cancer cells. In a therapeutic study, DU145 solid cancer‐bearing mice were i.v. injected thrice with BPA‐PEG‐LP encapsulating doxorubicin (BPA‐PEG‐LPDOX, 2 mg/kg/day as the DOX dosage) or PEG‐modified liposomes encapsulating DOX (PEG‐LPDOX). As a result, BPA‐PEG‐LPDOX significantly suppressed the growth of the DU145 cancer cells, whereas PEG‐LPDOX at the same dosage as DOX showed little anti‐cancer effect. The present study suggested that BPA‐PEG‐LP could be a useful drug carrier for the treatment of human prostate cancers.
BPA bound to human prostate cancer cells via the cell‐surface sugar chains terminating in galactose, resulting that BPA recognized to cancerous, but not to normal, human prostate tissue.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.12839</identifier><identifier>PMID: 26495901</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Antineoplastic drugs ; Antitumor agents ; Bauhinia ; Bauhinia purprea agglutinin ; Cancer therapies ; Cell Line, Tumor ; Cell surface ; Cytotoxicity ; Doxorubicin ; Doxorubicin - administration & dosage ; Doxorubicin - analogs & derivatives ; Doxorubicin - pharmacokinetics ; drug delivery system ; Drug delivery systems ; Drugs ; Efficiency ; Glycolipids ; Glycoproteins ; Humans ; Laboratories ; Lectins ; Lipids ; liposome ; Liposomes ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Nanoparticles ; Original ; Plant Lectins - administration & dosage ; Plant Lectins - pharmacokinetics ; Polyethylene glycol ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - pharmacokinetics ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Proteins ; Researchers ; targeting ; Xenograft Model Antitumor Assays</subject><ispartof>Cancer science, 2016-01, Vol.107 (1), p.53-59</ispartof><rights>2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5379-6a1fba13ff3c6a9f24244b43d24f764d8d8df9712ae6b7d952c5a445167273843</citedby><cites>FETCH-LOGICAL-c5379-6a1fba13ff3c6a9f24244b43d24f764d8d8df9712ae6b7d952c5a445167273843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724813/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724813/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26495901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ikemoto, Keisuke</creatorcontrib><creatorcontrib>Shimizu, Kosuke</creatorcontrib><creatorcontrib>Ohashi, Kento</creatorcontrib><creatorcontrib>Takeuchi, Yoshihito</creatorcontrib><creatorcontrib>Shimizu, Motohiro</creatorcontrib><creatorcontrib>Oku, Naoto</creatorcontrib><title>Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>Bauhinia purprea agglutinin (BPA) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA‐PEG‐modified liposomes (BPA‐PEG‐LP) encapsulating anticancer drugs for the treatment of prostate cancer. We examined the tumor targetability of BPA‐PEG‐LP with human prostate cancer DU145 cells, and observed that fluorescently labeled BPA‐PEG‐LP dominantly associated with the cells via the interaction between liposome‐surface BPA and cell‐surface galactosyl molecules. We also observed that BPA‐PEG‐LP accumulated in the prostate cancer tissue after the i.v. injection to DU145 solid cancer‐bearing mice, and strongly bound to the cancer cells. In a therapeutic study, DU145 solid cancer‐bearing mice were i.v. injected thrice with BPA‐PEG‐LP encapsulating doxorubicin (BPA‐PEG‐LPDOX, 2 mg/kg/day as the DOX dosage) or PEG‐modified liposomes encapsulating DOX (PEG‐LPDOX). As a result, BPA‐PEG‐LPDOX significantly suppressed the growth of the DU145 cancer cells, whereas PEG‐LPDOX at the same dosage as DOX showed little anti‐cancer effect. The present study suggested that BPA‐PEG‐LP could be a useful drug carrier for the treatment of human prostate cancers.
BPA bound to human prostate cancer cells via the cell‐surface sugar chains terminating in galactose, resulting that BPA recognized to cancerous, but not to normal, human prostate tissue.</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Bauhinia</subject><subject>Bauhinia purprea agglutinin</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Cell surface</subject><subject>Cytotoxicity</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Doxorubicin - pharmacokinetics</subject><subject>drug delivery system</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Efficiency</subject><subject>Glycolipids</subject><subject>Glycoproteins</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Lectins</subject><subject>Lipids</subject><subject>liposome</subject><subject>Liposomes</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Nanoparticles</subject><subject>Original</subject><subject>Plant Lectins - administration & dosage</subject><subject>Plant Lectins - pharmacokinetics</subject><subject>Polyethylene glycol</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - pharmacokinetics</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Proteins</subject><subject>Researchers</subject><subject>targeting</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kTtOxDAQhi0EYpdHwQVQJCqKgF-J4wZpWfGSkCiA2ppN7F2jJA52AqLjCJyRk2BYWEGBpxhr_PmfsX-E9gg-InEdlxCOCC2YXENjwrhMBcb5-tdepBIzOkJbITxgzHIu-SYa0ZgzickY3Z3CsLCthaQbfOc1JDCf10MfS-3761vjKmusrpLadi64RofEOJ8shgbapPMu9NDrpIS21D7p4_W-0W2_gzYM1EHvfudtdH9-dje9TK9vLq6mk-u0zJiQaQ7EzIAwY1iZgzSUU85nnFWUG5HzqohhpCAUdD4TlcxomQHnGckFFazgbBudLHW7YdboqoytPdSq87YB_6IcWPX3pLULNXdPigvKC8KiwMG3gHePgw69enCDb-PMitKiIJhS-UkdLqkyPjh4bVYdCFafBqhogPoyILL7v0dakT8_HoHjJfBsa_3yv5KaTm6Xkh_XRJJD</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Ikemoto, Keisuke</creator><creator>Shimizu, Kosuke</creator><creator>Ohashi, Kento</creator><creator>Takeuchi, Yoshihito</creator><creator>Shimizu, Motohiro</creator><creator>Oku, Naoto</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>201601</creationdate><title>Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment</title><author>Ikemoto, Keisuke ; Shimizu, Kosuke ; Ohashi, Kento ; Takeuchi, Yoshihito ; Shimizu, Motohiro ; Oku, Naoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5379-6a1fba13ff3c6a9f24244b43d24f764d8d8df9712ae6b7d952c5a445167273843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Bauhinia</topic><topic>Bauhinia purprea agglutinin</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Cell surface</topic><topic>Cytotoxicity</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Doxorubicin - pharmacokinetics</topic><topic>drug delivery system</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Efficiency</topic><topic>Glycolipids</topic><topic>Glycoproteins</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Lectins</topic><topic>Lipids</topic><topic>liposome</topic><topic>Liposomes</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Nanoparticles</topic><topic>Original</topic><topic>Plant Lectins - administration & dosage</topic><topic>Plant Lectins - pharmacokinetics</topic><topic>Polyethylene glycol</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - pharmacokinetics</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Proteins</topic><topic>Researchers</topic><topic>targeting</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ikemoto, Keisuke</creatorcontrib><creatorcontrib>Shimizu, Kosuke</creatorcontrib><creatorcontrib>Ohashi, Kento</creatorcontrib><creatorcontrib>Takeuchi, Yoshihito</creatorcontrib><creatorcontrib>Shimizu, Motohiro</creatorcontrib><creatorcontrib>Oku, Naoto</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ikemoto, Keisuke</au><au>Shimizu, Kosuke</au><au>Ohashi, Kento</au><au>Takeuchi, Yoshihito</au><au>Shimizu, Motohiro</au><au>Oku, Naoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2016-01</date><risdate>2016</risdate><volume>107</volume><issue>1</issue><spage>53</spage><epage>59</epage><pages>53-59</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>Bauhinia purprea agglutinin (BPA) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA‐PEG‐modified liposomes (BPA‐PEG‐LP) encapsulating anticancer drugs for the treatment of prostate cancer. We examined the tumor targetability of BPA‐PEG‐LP with human prostate cancer DU145 cells, and observed that fluorescently labeled BPA‐PEG‐LP dominantly associated with the cells via the interaction between liposome‐surface BPA and cell‐surface galactosyl molecules. We also observed that BPA‐PEG‐LP accumulated in the prostate cancer tissue after the i.v. injection to DU145 solid cancer‐bearing mice, and strongly bound to the cancer cells. In a therapeutic study, DU145 solid cancer‐bearing mice were i.v. injected thrice with BPA‐PEG‐LP encapsulating doxorubicin (BPA‐PEG‐LPDOX, 2 mg/kg/day as the DOX dosage) or PEG‐modified liposomes encapsulating DOX (PEG‐LPDOX). As a result, BPA‐PEG‐LPDOX significantly suppressed the growth of the DU145 cancer cells, whereas PEG‐LPDOX at the same dosage as DOX showed little anti‐cancer effect. The present study suggested that BPA‐PEG‐LP could be a useful drug carrier for the treatment of human prostate cancers.
BPA bound to human prostate cancer cells via the cell‐surface sugar chains terminating in galactose, resulting that BPA recognized to cancerous, but not to normal, human prostate tissue.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>26495901</pmid><doi>10.1111/cas.12839</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2016-01, Vol.107 (1), p.53-59 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4724813 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; PubMed Central |
| subjects | Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic drugs Antitumor agents Bauhinia Bauhinia purprea agglutinin Cancer therapies Cell Line, Tumor Cell surface Cytotoxicity Doxorubicin Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Doxorubicin - pharmacokinetics drug delivery system Drug delivery systems Drugs Efficiency Glycolipids Glycoproteins Humans Laboratories Lectins Lipids liposome Liposomes Male Mice Mice, Inbred BALB C Mice, Nude Nanoparticles Original Plant Lectins - administration & dosage Plant Lectins - pharmacokinetics Polyethylene glycol Polyethylene Glycols - administration & dosage Polyethylene Glycols - pharmacokinetics Prostate cancer Prostatic Neoplasms - drug therapy Proteins Researchers targeting Xenograft Model Antitumor Assays |
| title | Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T06%3A47%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bauhinia%20purprea%20agglutinin%E2%80%90modified%20liposomes%20for%20human%20prostate%20cancer%20treatment&rft.jtitle=Cancer%20science&rft.au=Ikemoto,%20Keisuke&rft.date=2016-01&rft.volume=107&rft.issue=1&rft.spage=53&rft.epage=59&rft.pages=53-59&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.12839&rft_dat=%3Cproquest_pubme%3E2288102293%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2288102293&rft_id=info:pmid/26495901&rfr_iscdi=true |